PT-141 (10ml)
$45.00
A synthetic melanocortin receptor agonist studied in laboratory research for its interactions with MC3R and MC4R and its contributions to the neuroscience of sexual function biology.
Buy 1
SAVE 0%
Buy 3
SAVE 20%
Buy 5
SAVE 33%
Buy 7+
SAVE 50%
Description
PT-141 (Bremelanotide) is a synthetic cyclic peptide melanocortin receptor agonist derived from Melanotan II, optimized for selective activity at MC3R and MC4R in the central nervous system. It has been the subject of both laboratory and clinical research into the neurobiology of sexual function, with Bremelanotide receiving FDA approval in 2019 (as Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
The clinical development and approval of Bremelanotide has provided a substantial published foundation of receptor pharmacology, CNS signaling, and safety data to support laboratory research. Studies have explored its central versus peripheral mechanisms, its comparative profile relative to Melanotan II, and the broader neuroscience of melanocortin receptor-mediated sexual function pathways that PT-141 has helped characterize.
Supplied as a lyophilized Research Use Only (RUO) material, analytically verified for identity and purity with batch-specific Certificate of Analysis documentation.
